Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183884 · ClinicalTrials.gov registry record · Phase 2
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01183884: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01183884 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01183884, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
Interventions
- BIOLOGICAL 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-08 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183884
The ClinicalTrials.gov registry entry for NCT01183884 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid is the first listed.
NCT01183884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01183884 about?
NCT01183884 is a clinical study titled "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma". The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
What is the current status of trial NCT01183884?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2010-08. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT01183884?
The interventions under investigation include: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid (BIOLOGICAL).
Who is sponsoring clinical trial NCT01183884?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.